Fozivudine Tidoxil
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Fozivudine Tidoxil
- DrugBank Accession Number
- DB12423
- Background
Fozivudine Tidoxil has been used in trials studying the treatment of HIV Infections.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 745.96
Monoisotopic: 745.421322213 - Chemical Formula
- C35H64N5O8PS
- Synonyms
- Fozivudine Tidoxil
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as pyrimidones. These are compounds that contain a pyrimidine ring, which bears a ketone. Pyrimidine is a 6-membered ring consisting of four carbon atoms and two nitrogen centers at the 1- and 3- ring positions.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Diazines
- Sub Class
- Pyrimidines and pyrimidine derivatives
- Direct Parent
- Pyrimidones
- Alternative Parents
- Dialkyl phosphates / Hydropyrimidines / Tetrahydrofurans / Heteroaromatic compounds / Vinylogous amides / Lactams / Azo imides / Azo compounds / Ureas / Sulfenyl compounds show 7 more
- Substituents
- Alkyl phosphate / Aromatic heteromonocyclic compound / Azacycle / Azo compound / Azo imide / Dialkyl ether / Dialkyl phosphate / Dialkylthioether / Ether / Heteroaromatic compound show 19 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 687805287F
- CAS number
- 141790-23-0
- InChI Key
- IBHARWXWOCPXCR-WELGVCPWSA-N
- InChI
- InChI=1S/C35H64N5O8PS/c1-4-6-8-10-12-14-15-17-19-21-23-50-28-30(45-22-20-18-16-13-11-9-7-5-2)26-46-49(43,44)47-27-32-31(38-39-36)24-33(48-32)40-25-29(3)34(41)37-35(40)42/h25,30-33H,4-24,26-28H2,1-3H3,(H,43,44)(H,37,41,42)/t30?,31-,32+,33+/m0/s1
- IUPAC Name
- {[(2S,3S,5R)-3-azido-5-(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methoxy}[2-(decyloxy)-3-(dodecylsulfanyl)propoxy]phosphinic acid
- SMILES
- CCCCCCCCCCCCSCC(COP(O)(=O)OC[C@H]1O[C@H](C[C@@H]1N=[N+]=[N-])N1C=C(C)C(=O)NC1=O)OCCCCCCCCCC
References
- General References
- Not Available
- External Links
- PubChem Compound
- 64140
- PubChem Substance
- 347828666
- ChemSpider
- 57716
- ChEMBL
- CHEMBL3989603
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count Not Available Completed Treatment Human Immunodeficiency Virus (HIV) Infections 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00252 mg/mL ALOGPS logP 5.45 ALOGPS logP 9.53 Chemaxon logS -5.5 ALOGPS pKa (Strongest Acidic) 1.89 Chemaxon pKa (Strongest Basic) -3.9 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 8 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 153.06 Å2 Chemaxon Rotatable Bond Count 31 Chemaxon Refractivity 197.11 m3·mol-1 Chemaxon Polarizability 85.2 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 255.98213 predictedDeepCCS 1.0 (2019) [M+H]+ 257.80704 predictedDeepCCS 1.0 (2019) [M+Na]+ 263.41287 predictedDeepCCS 1.0 (2019)
Drug created at October 20, 2016 22:20 / Updated at February 21, 2021 18:53